Phase 1 OL, Dose Escalating, Multiple Dose Study To Determine The Safety, Tolerability, MTD, And Pharmacokinetics Of MPC-2130 Administered As Daily IV Infusions For 5 Days, Repeated Every 21 Days, In Patients With Refractory Cancer
Phase 1 Open-label treatment with MPC-2130 for subjects with refractory cancer.
100 项与 MPC-2130 相关的专利(医药)